vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and SAFE & GREEN HOLDINGS CORP. (OLOX). Click either name above to swap in a different company.

SAFE & GREEN HOLDINGS CORP. is the larger business by last-quarter revenue ($1.8M vs $1.4M, roughly 1.3× FATE THERAPEUTICS INC). On growth, FATE THERAPEUTICS INC posted the faster year-over-year revenue change (-26.4% vs -55.8%). Over the past eight quarters, FATE THERAPEUTICS INC's revenue compounded faster (-15.7% CAGR vs -34.8%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Safe Auto Insurance Company is an American property and casualty auto insurance carrier. It is a privately held carrier and provider of state-minimum private-passenger auto insurance for drivers in the nonstandard insurance market in 20 states across the US, including Oregon, Ohio, Indiana, Kentucky, Georgia, Pennsylvania, South Carolina, Tennessee, Louisiana, Mississippi, Illinois, Missouri, Arizona, Oklahoma, Kansas, Virginia, Texas, California, Alabama, and Colorado.

FATE vs OLOX — Head-to-Head

Bigger by revenue
OLOX
OLOX
1.3× larger
OLOX
$1.8M
$1.4M
FATE
Growing faster (revenue YoY)
FATE
FATE
+29.4% gap
FATE
-26.4%
-55.8%
OLOX
Faster 2-yr revenue CAGR
FATE
FATE
Annualised
FATE
-15.7%
-34.8%
OLOX

Income Statement — Q4 FY2025 vs Q3 FY2024

Metric
FATE
FATE
OLOX
OLOX
Revenue
$1.4M
$1.8M
Net Profit
$-3.7M
Gross Margin
-7.2%
Operating Margin
-127.8%
Net Margin
-212.0%
Revenue YoY
-26.4%
-55.8%
Net Profit YoY
37.9%
-3.0%
EPS (diluted)
$-113.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
OLOX
OLOX
Q4 25
$1.4M
Q3 25
$1.7M
Q2 25
$1.9M
Q1 25
$1.6M
Q4 24
$1.9M
Q3 24
$3.1M
$1.8M
Q2 24
$6.8M
$1.3M
Q1 24
$1.9M
Net Profit
FATE
FATE
OLOX
OLOX
Q4 25
Q3 25
$-32.3M
Q2 25
$-34.1M
Q1 25
$-37.6M
Q4 24
Q3 24
$-47.7M
$-3.7M
Q2 24
$-38.4M
$-4.7M
Q1 24
$-48.0M
Gross Margin
FATE
FATE
OLOX
OLOX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-7.2%
Q2 24
9.3%
Q1 24
Operating Margin
FATE
FATE
OLOX
OLOX
Q4 25
Q3 25
-1995.1%
Q2 25
-1938.5%
Q1 25
-2534.1%
Q4 24
Q3 24
-1703.9%
-127.8%
Q2 24
-665.7%
-150.9%
Q1 24
-2652.9%
Net Margin
FATE
FATE
OLOX
OLOX
Q4 25
Q3 25
-1852.4%
Q2 25
-1786.6%
Q1 25
-2309.5%
Q4 24
Q3 24
-1551.0%
-212.0%
Q2 24
-567.4%
-373.1%
Q1 24
-2493.7%
EPS (diluted)
FATE
FATE
OLOX
OLOX
Q4 25
Q3 25
$-0.27
Q2 25
$-0.29
Q1 25
$-0.32
Q4 24
Q3 24
$-0.40
$-113.82
Q2 24
$-0.33
$-3.31
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
OLOX
OLOX
Cash + ST InvestmentsLiquidity on hand
$203.7M
$257.0K
Total DebtLower is stronger
$6.6M
Stockholders' EquityBook value
$207.2M
$-8.2M
Total Assets
$318.9M
$9.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
OLOX
OLOX
Q4 25
$203.7M
Q3 25
$215.4M
Q2 25
$222.8M
Q1 25
$240.4M
Q4 24
$279.1M
Q3 24
$296.9M
$257.0K
Q2 24
$304.9M
$1.0M
Q1 24
$121.3M
Total Debt
FATE
FATE
OLOX
OLOX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$6.6M
Q2 24
$12.6M
Q1 24
Stockholders' Equity
FATE
FATE
OLOX
OLOX
Q4 25
$207.2M
Q3 25
$234.1M
Q2 25
$261.4M
Q1 25
$288.4M
Q4 24
$318.7M
Q3 24
$362.3M
$-8.2M
Q2 24
$397.0M
$-5.7M
Q1 24
$426.1M
Total Assets
FATE
FATE
OLOX
OLOX
Q4 25
$318.9M
Q3 25
$343.7M
Q2 25
$371.6M
Q1 25
$398.7M
Q4 24
$440.7M
Q3 24
$495.0M
$9.8M
Q2 24
$528.8M
$20.9M
Q1 24
$569.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
OLOX
OLOX
Operating Cash FlowLast quarter
$-106.1M
Free Cash FlowOCF − Capex
$-112.0M
FCF MarginFCF / Revenue
-8183.9%
Capex IntensityCapex / Revenue
434.8%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
OLOX
OLOX
Q4 25
$-106.1M
Q3 25
$-24.4M
Q2 25
$-24.6M
Q1 25
$-33.8M
Q4 24
$-122.9M
Q3 24
$-29.4M
Q2 24
$-32.3M
$-3.7M
Q1 24
$-33.4M
Free Cash Flow
FATE
FATE
OLOX
OLOX
Q4 25
$-112.0M
Q3 25
$-26.6M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
Q3 24
$-29.9M
Q2 24
$-32.4M
$-3.7M
Q1 24
$-33.4M
FCF Margin
FATE
FATE
OLOX
OLOX
Q4 25
-8183.9%
Q3 25
-1526.5%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
Q3 24
-973.1%
Q2 24
-477.8%
-296.7%
Q1 24
-1736.9%
Capex Intensity
FATE
FATE
OLOX
OLOX
Q4 25
434.8%
Q3 25
126.5%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
Q3 24
16.1%
0.0%
Q2 24
0.8%
2.0%
Q1 24
4.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons